Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors—implications for therapeutic potential
Targeted treatments are needed for advanced adult-type granulosa cell tumors (AGCTs). We set out to assess tumor tissue and circulating levels of TNF-related apoptosis-inducing ligand (TRAIL), a promising anti-cancer cytokine, in patients affected by AGCT. We analyzed tissue expression of TRAIL in 127 AGCTs using immunohistochemistry or RT-PCR. Soluble TRAIL was measured by means of ELISA from 141 AGCT patient serum samples, as well as the conditioned media of 15 AGCT patient-derived primary cell cultures, and the KGN cell line. Tissue and serum TRAIL levels were analyzed in relationship with clinical parameters, and serum estradiol, FSH, and LH levels. We found that AGCT samples expressed TRAIL mRNA and protein at levels comparable to normal granulosa cells. AGCT cells did not release soluble TRAIL. TRAIL protein levels were decreased in tumors over 10 cm in diameter (p = 0.04). Consistently, circulating TRAIL levels correlated negatively to tumor dimension (p = 0.01). Circulating TRAIL levels negatively associated with serum estradiol levels. In multiple regression analysis, tumor size was an independent factor contributing to the decreased levels of soluble TRAIL in AGCT patients. AGCTs associate with significantly decreased tumor tissue and serum TRAIL levels in patients with a large tumor mass. These findings encourage further study of agonistic TRAIL treatments in patients with advanced or recurrent AGCT.
KeywordsEstradiol FSH GATA4 Granulosa cell tumor LH Ovarian cancer Targeted treatment TRAIL
We thank Dr. Annika Riska and the staff from the Department of Obstetrics and Gynecology of Helsinki University Central Hospital for patient recruitment, Dr. Noora Andersson for excellent practical assistance, and PhD Emmi Tikkanen for statistical advice. This study was supported by grants from from the Academy of Finland, the Clinical Chemistry Research Foundation Finland, the Helsinki University Central Hospital Research Funds, the Maud Kuistila Memorial Foundation, the Sigrid Juselius Foundation, and the Sladjana M. Crosley Foundation for AGCT research.
AF collected the samples, produced and analyzed the data, carried out the statistical analyses and wrote the manuscript; GZ produced and analyzed the data and drafted the manuscript; U-MH and MP performed immunohistochemistry, cell culture studies, qPCR, and analyzed the data; PS, LU-K and MH collected the samples, conceived of the study and interpreted the data; All authors wrote the manuscript, and read and approved this version of the manuscript.
Compliance with ethical standards
The ethical committee of Helsinki University Central Hospital (HUCH) and the National Supervisory Authority for Welfare and Health in Finland approved the study, and all patients gave their informed consent.
Conflicts of Interest
- 26.Gibellini D, Zauli G, Re MC, Milani D, Furlini G, Caramelli E, et al. Recombinant human immunodeficiency virus type-1 (HIV-1) Tat protein sequentially up-regulates IL-6 and TGF-beta 1 mRNA expression and protein synthesis in peripheral blood monocytes. Br J Haematol. 1994;88:261–7.CrossRefPubMedGoogle Scholar
- 29.Secchiero P, Gonelli A, Celeghini C, Mirandola P, Guidotti L, Visani G, et al. Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. Blood. 2001;98:2220–8.CrossRefPubMedGoogle Scholar
- 30.Anttonen M, Unkila-Kallio L, Leminen A, Butzow R, Heikinheimo M. High GATA-4 expression associates with aggressive behavior, whereas low anti-Mullerian hormone expression associates with growth potential of ovarian granulosa cell tumors. J Clin Endocrinol Metab. 2005;90:6529–35.CrossRefPubMedGoogle Scholar
- 32.Farkkila A, Pihlajoki M, Tauriala H, Butzow R, Leminen A, Unkila-Kallio L, et al. Serum vascular endothelial growth factor A (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in vitro. J Clin Endocrinol Metab. 2011;96:E1973–81.CrossRefPubMedGoogle Scholar